Novel NPY Y2 receptor agonist BI 1820237 showed synergistic anti-obesity efficacy when combined with existing weight loss agents, targeting a new peptide receptor for weight management.
Key findingNovel NPY Y2 receptor agonist BI 1820237 showed synergistic anti-obesity efficacy when combined with
What the researchers found
Novel NPY Y2 receptor agonist BI 1820237 showed synergistic anti-obesity efficacy when combined with existing weight loss agents, targeting a new peptide receptor for weight management.
Why it matters
Relevant to peptide therapeutics.
How the study worked
In publication.
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.
Molecular metabolism, 99, 102205
Citation
Augustin, Robert; Oldenburger, Anouk; Baader-Pagler, Tamara; Zimmermann, Tina; Borghardt, Jens; Hecksher-Sørensen, Jacob; Baljuls, Angela; Reindl, Wolfgang; Krawczyk, Bartlomiej; Martel, Eric; Brennauer, Albert; Peters, Stefan; Grube, Achim; Rudkjaer, Lise Biehl; Haebel, Peter. (2025). Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.. Molecular metabolism, 99, 102205. https://doi.org/10.1016/j.molmet.2025.102205